Clinical trials: Ophthalmic Solutions
Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral
Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in normal tension glaucoma patients.
- Conditions
- Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral, Low-Tension Glaucoma, Unspecified Eye, Glaucoma
- Trial name
- Nightingale (NCT06030193)
- Testing
- QLS-111 ophthalmic solution (0.015%), Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Qlaris Bio, Inc.
Myopia
BIOCLEAN MPS (Multi-Purpose Solution) VII in Combination With Biofinity Lens: A Two Week Crossover Study
Two week, Open Label, randomized, bilateral, crossover, 1 week of daily wear in each combination (lens / disinfecting cleaning system).
- Trial name
- NCT02537730
- Testing
- Bioclean MPS VII, Aosept Clearcare, comfilcon A
- Where
- 3 sites in Japan
- Volunteers
- 33 people
- Sponsor
- CooperVision, Inc.
Dry Eye Syndromes
A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye
The purpose of this study is to assess the safety and effectiveness of SI-614 solution compared with placebo solution in treating patients with dry eye
- Trial name
- NCT01558999
- Testing
- High concentration SI-614, Low concentration SI-614, Vehicle
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Seikagaku Corporation
Dry Eye Syndrome
Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline
The purpose of this study is to evaluate the ocular retention time of Systane Ultra compared to Hialid and saline.
- Trial name
- NCT01252121
- Testing
- Systane Ultra Lubricant Eye Drops, Hialid 0.1 Artificial Tears Eye Drops, Unisol 4 Saline Solution
- Volunteers
- 27 people
- Sponsor
- Alcon Research
Hypersensitivity, Allergic Rhinitis
Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis
The purpose of this 2-year study is to assess the sustained clinical efficacy and safety of 300 IR/day of a sublingual solution of birch pollen allergen extract starting 4 months prior to the birch pollen season and continuing…
- Conditions
- Hypersensitivity, Allergic Rhinitis, Allergic Conjunctivitis, Seasonal Allergy
- Trial name
- NCT01731249
- Testing
- Birch pollen allergen extract
- Where
- 11 sites in Czechia, Denmark and 9 more
- Volunteers
- 574 people
- Sponsor
- Stallergenes Greer
Vernal Keratoconjunctivitis
Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis
The objective of this study is to compare the efficacy of two different dosing regimen of NOVA22007 (1mg/ml ciclosporin/cyclosporine) eye drops, emulsion versus placebo (vehicle of the formulation) administered four times a day…
- Trial name
- NCT01751126
- Testing
- NOVA22007 ''Ciclosporin''
- Where
- 46 sites in United States, Croatia and 9 more
- Volunteers
- 169 people
- Sponsor
- Santen SAS
Dry Eye
A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease
Protocol AXR201701 is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study carried out in 2 stages (Stage 1: AXR-159 Ophthalmic Solution (30 mg/mL or 50 mg/mL); Stage 2: AXR-159 Ophthalmic Solution…
- Trial name
- NCT03598699
- Testing
- AXR-159, Vehicle
- Where
- 3 sites in United States
- Volunteers
- 102 people
- Sponsor
- AxeroVision, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting
To evaluate the IOP lowering efficacy of netarsudil ophthalmic solution 0.02% when used as monotherapy or when used concomitantly with other IOP-lowering agents in subjects with elevated IOP due to open angle glaucoma or ocular…
- Trial name
- NCT03808688
- Testing
- Netarsudil Ophthalmic Solution 0.02%
- Where
- 22 sites in United States
- Volunteers
- 261 people
- Sponsor
- Aerie Pharmaceuticals
Seasonal Allergic Conjunctivitis
Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)
This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal…
- Trial name
- NCT01435460
- Testing
- Loteprednol etabonate 0.2%, Olopatadine 0.1%
- Where
- Singapore
- Volunteers
- 300 people
- Sponsor
- Bausch & Lomb Incorporated
Conjunctivitis, Bacterial
Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis
To demonstrate the efficacy of T1225 1.5% eye drops, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis, and to assess the safety
- Trial name
- NCT00357773
- Testing
- Azithromycin (T1225)
- Sponsor
- Laboratoires Thea
Primary Open Angle Glaucoma, Intraocular Pressure
Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Treatment With Either Beta-blockers or Prostaglandins Eye Drops
Elevated intraocular pressure is still the main risk factor for development and progression of glaucoma. Several drugs exist on the market that may decrease IOP in glaucomatous patients.
- Trial name
- NCT00863811
- Where
- Italy
- Sponsor
- Sooft Italia
Dry Eye
An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
The primary objective of this study was to assess the efficacy and safety of rhNGF when administered as eye drops to patients with dry eye The secondary objectives of this study were: To assess change from baseline in Symptom…
- Trial name
- NCT03019627
- Testing
- NGF, Vehicle
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Dompé Farmaceutici S.p.A
Dry Eye, Dry Eye Syndromes
Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye
Tangible Hydra-PEG is a novel coating technology designed to improve lens wettability, deposit resistance, and tear film breakup time.
- Trial name
- NCT03417505
- Testing
- Scleral lenses treated with Tangible Hydra-PEG, Untreated scleral lenses
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tangible Science
Cataract, Phacoemulsification Cataract Surgery
Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification
The purpose of this study is to evaluate efficacy and safety of the ophthalmic solution PRO-155 in patients post phacoemulsification.
- Trial name
- NCT01657266
- Testing
- PRO-155, Nevanac
- Where
- Mexico
- Volunteers
- 160 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Blepharoptosis
A Study in Chinese Patients With Acquired Blepharoptosis
This is a Phase III Study to evaluate the efficacy and safety of STN1013800 Ophthalmic Solution in Chinese Patients with Acquired Blepharoptosis.
- Trial name
- NCT06683651
- Testing
- STN1013800 ophthalmic solution, STN1013800 ophthalmic solution Liquid Base, without STN1013800
- Where
- 23 sites in China
- Volunteers
- 180 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open-angle Glaucoma and Ocular Hypertension
Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6
This is a randomized, double-masked, parallel-group, multi-center study. Subjects diagnosed with POAG or OHT who meet eligibility criteria at Visit 1 (Screening) will wash out their current topical IOP lowering medication(s), if…
- Trial name
- NCT03858894
- Testing
- DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID
- Where
- 13 sites in United States
- Volunteers
- 98 people
- Sponsor
- Santen Inc.
Presbyopia
Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia
Safety and efficacy of POS in participants with presbyopia
- Trial name
- VEGA-3 (NCT06542497)
- Testing
- 0.75% phentolamine ophthalmic solution
- Where
- 39 sites in United States
- Volunteers
- 569 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution.
- Trial name
- NCT02558374
- Testing
- AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID
- Where
- United States
- Volunteers
- 708 people
- Sponsor
- Aerie Pharmaceuticals
Cataract
Safety and Efficacy Study of an Ophthalmic Solution in Patients With Age-Related Cataract
The purpose of this study is to determine the safety and efficacy of C-KAD Ophthalmic Solution in improving visual acuity relative to placebo in patients with age-related cataract
- Trial name
- NCT00793091
- Testing
- C-KAD Ophthalmic Solution
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Chakshu Research, Inc.
Open-angle Glaucoma, Ocular Hypertension
A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension
The objective of this study is to investigate whether the IOP (intraocular pressure) -lowering effect of DE-111A (preservative-free fixed dose combination of 0.0015% tafluprost and 0.5% timolol eye drops, administered one drop a…
- Trial name
- NCT03822559
- Testing
- A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL, A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL
- Where
- 2 sites in China
- Volunteers
- 219 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.